Michelle Petri

Michelle Petri

Auto-generated profile, based on publicly available information

Michelle Petri

Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2012 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MPMichelle Petri
Michelle Petri
AOAna‐Maria Orbai
Ana‐Maria Orbai
GAGraciela S. Alarcón
Graciela S. Alarcón
CGCaroline Gordon
Caroline Gordon
JMJoan T. Merrill
Joan T. Merrill
LMLaurence S. Magder
Laurence S. Magder
Objective: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE.Methods: The classification criteria were derived from a set of 702 expert‐rated patient scenarios. Recursive partitioning was used to derive an initial rule that was simplified and refined based on SLICC physician consensus. The SLICC group validated the classification criteria in a new validation sample of 690 new expert‐rated patient scenarios.Results: Seventeen criteria were identified. In the derivation set, the SLICC classification criteria resulted in fewer misclassifications compared with the current ACR classification criteria (49 versus 70; P = 0.0082) and had greater sensitivity (94% versus 86%; P < 0.0001) and equal specificity (92% versus 93%; P = 0.39). In the validation set, the SLICC classification criteria resulted in fewer misclassifications compared with the current ACR classification criteria (62 versus 74; P = 0.24) and had greater sensitivity (97% versus 83%; P < 0.0001) but lower specificity (84% versus 96%; P < 0.0001).Conclusion: The new SLICC classification criteria performed well in a large set of patient scenarios rated by experts. According to the SLICC rule for the classification of SLE, the patient must satisfy at least 4 criteria, including at least one clinical criterion and one immunologic criterion OR the patient must have biopsy‐proven lupus nephritis in the presence of antinuclear antibodies or anti–double‐stranded DNA antibodies.

12 October 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
AFAntonis Fanouriakis
Antonis Fanouriakis
MKMyrto Kostopoulou
Myrto Kostopoulou
JAJeanette Andersen
Jeanette Andersen
MAMartin Aringer
Martin Aringer
ALArnaud L
Arnaud L
DBDimitrios T Boumpas
Dimitrios T Boumpas
Objectives To update the EULAR recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence. Methods An international Task Force formed the questions for the systematic literature reviews (January 2018–December 2022), followed by formulation and finalisation of the statements after a series of meetings. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned, and participants finally provided their level of agreement with each item. Results The Task Force agreed on 5 overarching principles and 13 recommendations, concerning the use of hydroxychloroquine (HCQ), glucocorticoids (GC), immunosuppressive drugs (ISDs) (including methotrexate, mycophenolate, azathioprine, cyclophosphamide (CYC)), calcineurin inhibitors (CNIs, cyclosporine, tacrolimus, voclosporin) and biologics (belimumab, anifrolumab, rituximab). Advice is also provided on treatment strategies and targets of therapy, assessment of response, combination and sequential therapies, and tapering of therapy. HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual’s risk for flares and retinal toxicity. GC are used as ‘bridging therapy’ during periods of disease activity; for maintenance treatment, they should be minimised to equal or less than 5 mg/day (prednisone equivalent) and, when possible, withdrawn. Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation. CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor drugs, and add-on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered. Updated specific recommendations are also provided for cutaneous, neuropsychiatric and haematological disease, SLE-associated antiphospholipid syndrome, kidney protection, as well as preventative measures for infections, osteoporosis, cardiovascular disease. Conclusion The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.

1 January 2019 in Journal of Autoimmunity
Verified
Journal Article
Closed access
AFAndrea Fava
Andrea Fava
MPMichelle Petri
Michelle Petri

28 August 2023 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
MBMedha Barbhaiya
Medha Barbhaiya
SZStephane Zuily
Stephane Zuily
RNRay Naden
Ray Naden
AHAlison Hendry
Alison Hendry
FMFlorian Manneville
Florian Manneville
TCThe Acr/Eular Aps Classification Criteria Collaborators
The Acr/Eular Aps Classification Criteria Collaborators

28 August 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MBMedha Barbhaiya
Medha Barbhaiya
SZStephane Zuily
Stephane Zuily
RNRay Naden
Ray Naden
AHAlison Hendry
Alison Hendry
FMFlorian Manneville
Florian Manneville
RZRay Zuo
Ray Zuo
Objective To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods This international multidisciplinary initiative included four phases: (1) Phase I, criteria generation by surveys and literature review; (2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; (3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and (4) Phase IV, validation using independent adjudicators’ consensus as the gold standard. Results The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion, followed by additive weighted criteria (score range 1–7 points each) clustered into six clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and two laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti–β2-glycoprotein I antibodies). Patients accumulating at least three points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria vs the 2006 revised Sapporo classification criteria had a specificity of 99% vs 86%, and a sensitivity of 84% vs 99%. Conclusion These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.

24 November 2021 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
RVRonald F van Vollenhoven
Ronald F van Vollenhoven
GBGeorge Bertsias
George Bertsias
ADAndrea Doria
Andrea Doria
DIDavid Isenberg
David Isenberg
EMEric Morand
Eric Morand
CACynthia Aranow
Cynthia Aranow
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.